Novartis

Novartis CEO joins board of "responsible" AI firm Anthropic pharmaphorum12:18Novartis CEO Anthropic AI

Novartis CEO joins Anthropic’s board of directors Swiss Info02:27Novartis CEO Anthropic AI

Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE… Proactive Investors (US)10:31Excellergy Business (US) Pharma

Novartis to acquire Excellergy in deal worth up to $2bn PMLiVE06:06Excellergy Business (US) Pharma

Novartis whistleblower advances kickback lawsuit toward trial Bloomberg Law11:14

Novartis India announces cessation of director The Business Standard03:26Director India Pharma

Board of Novartis India appoints Gowree Gokhale as additional director The Business Standard03:26Director India Pharma

Switzerland's pharma group Novartis adds first Falcon 8X ch-aviation04:17Switzerland Pharma

From e-cigarettes to lab devices: surprising facts about Swiss patents Swiss Info04:14Pharma

Novartis targets Xolair successor in buyout of startup Excellergy BioPharma Dive12:06Xolair Excellergy

Novartis snaps up food allergy firm Excellergy for $2bn pharmaphorum06:01Xolair Excellergy

Novartis: Fabhalta cut kidney function decline by 49.3% In igan RTT News07:18Fabhalta Biotech Pharma

Latest News

In the last 4 hours

Anthropic Trust Appoints Novartis CEO to Board crypto.news17:14

Earlier today

Pharma Gains A Seat At The AI Table As Anthropic Taps Novartis’s Narasimhan Scrip Pharma Intelligence09:25

Novartis CEO joins Anthropic’s board of directors Swiss Info02:27

Yesterday

Novartis CEO joins board of "responsible" AI firm Anthropic pharmaphorum12:18 15-Apr-26

Novartis CEO Vas Narasimhan joins Anthropic’s board as biopharma’s ties to AI deepen FiercePharma10:48 15-Apr-26

Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and… Business Wire (Press Release)10:01 15-Apr-26

STAT Plus: Novartis CEO joins Anthropic’s board STAT09:46 15-Apr-26

From e-cigarettes to lab devices: surprising facts about Swiss patents Swiss Info04:14 15-Apr-26

Novartis Korea secures MFDS approval for first oral BTK inhibitor in CSU Korea Biomedical Review03:34 15-Apr-26

Anthropic’s oversight trust just hit majority control. The tipping-point was adding Novartis… Drug Discovery & Development00:05 15-Apr-26

In the last 7 days

In re Entresto (sacubitril/valsartan) Patent Litigation (Novartis Pharms. Corp. v. MSN Labs. Private Ltd. JD Supra15:34 14-Apr-26

Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its board The Economic Times12:52 14-Apr-26

Anthropic appoints Novartis CEO Vas Narasimhan to Board The Economic Times11:10 14-Apr-26

New long term social impact and sustainability targets Novartis (Press Release)06:36 13-Apr-26

Novartis cuts 114 more jobs at New Jersey HQ as restructuring rolls on FiercePharma10:58 10-Apr-26

Novartis pumps up community health footprint to tackle heart disease and cancer FiercePharma05:43 10-Apr-26

Novartis Loses Appeal to Halt Mississippi Drug Discount Law Bloomberg Law11:54 9-Apr-26

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting… Novartis (Press Release)01:30 9-Apr-26

In the last month

Switzerland's pharma group Novartis adds first Falcon 8X ch-aviation04:17 3-Apr-26

Top Tech Jobs: Anthropic, Novartis and Revolut are hiring Sunday Business Post08:01 2-Apr-26

Novartis to acquire Excellergy in deal worth up to $2bn PMLiVE06:06 1-Apr-26

Novartis Seeks To Block New Wash. 340B Drug-Pricing Law Law36021:51 31-Mar-26

Novartis Can't Nix FCA Suit Alleging MS Drug Kickbacks Law36021:51 31-Mar-26

Novartis Whistleblower Advances Kickback Lawsuit Toward Trial Bloomberg Law11:14 31-Mar-26

BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled… FiercePharma13:01 30-Mar-26

Novartis: Fabhalta Cut Kidney Function Decline By 49.3% In IgAN RTT News07:18 30-Mar-26

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% Novartis (Press Release)02:07 29-Mar-26

Novartis buying allergy firm Excellergy for $2B BioWorld16:53 27-Mar-26

Novartis Bolsters Immunology Pipeline With Excellergy Deal Zacks15:56 27-Mar-26

Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline Benzinga12:54 27-Mar-26

Novartis targets Xolair successor in buyout of startup Excellergy BioPharma Dive12:06 27-Mar-26

Novartis to acquire Excellergy, strengthening allergy pipeline with next-generation anti-IgE… Proactive Investors (US)10:31 27-Mar-26

Novartis To Acquire Excellergy, Expanding Allergy Leadership RTT News08:54 27-Mar-26

Novartis buys allergy specialist Excellergy for up to $2bn ShareCast08:41 27-Mar-26

Novartis to pay up to US$2 billion for US biotech firm Excellergy BNN Bloomberg08:02 27-Mar-26

Novartis to acquire Excellergy for $2bn upfront Pharmaceutical Business Review07:40 27-Mar-26

Novartis To Buy US Biotech In Up-To-$2B Allergy Drug Deal Law36007:12 27-Mar-26

Novartis snaps up food allergy firm Excellergy for $2bn pharmaphorum06:01 27-Mar-26

Novartis to Buy Excellergy in Deal Worth Up to $2 Billion (2) Bloomberg Law04:31 27-Mar-26

Novartis to buy Excellergy for up to $2 billion RTE03:38 27-Mar-26

Novartis India announces cessation of director The Business Standard03:26 27-Mar-26

Board of Novartis India appoints Gowree Gokhale as additional director The Business Standard03:26 27-Mar-26

Novartis to Acquire Excellergy in Deal Worth Up to $2 Billion Bloomberg Law02:33 27-Mar-26

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation Novartis (Press Release)02:08 27-Mar-26

Regina Hall Is Not Asking: Why Breast Health Literacy Is the Only Conversation That Matters… Black Enterprise09:38 26-Mar-26

AbbVie, Novartis Sue Wash. Over New 340B Drug-Pricing Law Law36021:46 25-Mar-26

Novartis sued by breast cancer patient over branded drug websites’ data-sharing practices FiercePharma12:09 25-Mar-26

Patient sues Novartis, claiming data-tracking privacy breach pharmaphorum09:26 25-Mar-26

Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma Dive08:54 25-Mar-26

Novartis unveils its investment and expansion plans for China to boost biopharm R&D footprint BioSpectrum Asia22:37 24-Mar-26

Novartis Sued Over Tracking Pixels on Drug-Discount Websites Bloomberg Law15:50 24-Mar-26

March 24 Business Watch: Helium capacity taken out in Qatar; Novartis to pay $2 billion for small molecule Chemical & Engineering News14:20 24-Mar-26

Scotland becomes first part of UK to screen all newborn babies for SMA PMLiVE08:55 24-Mar-26

CHA Biotech and Novartis Korea partner to establish platform for biotech innovation BioSpectrum Asia07:48 24-Mar-26

Novartis Faces Class Suit Over Patient Health Info Disclosure Law36019:14 23-Mar-26

Novartis joins Lilly, AZ in China expansion with $480M commitment to boost manufacturing, R&D FiercePharma10:59 23-Mar-26

Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment PMLiVE05:07 23-Mar-26

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 Novartis (Press Release)02:21 23-Mar-26

CHA Biotech, Novartis Korea partner to launch K-Bio open innovation center Korea Biomedical Review00:03 23-Mar-26

Art Deco building to be torn down for 200 homes despite dozens of objections The Argus, Sussex06:53 21-Mar-26

Synnovation’s PI3Kα inhibitor portfolio draws Novartis in $3B deal BioWorld16:41 20-Mar-26

Novartis Strikes $3B Oncology Deal for Breast Cancer Asset Zacks15:57 20-Mar-26

Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug Benzinga10:57 20-Mar-26

Novartis snaps up Synnovation's breast-cancer treatment for up to $3bn ShareCast09:32 20-Mar-26

Novartis To Buy Breast Cancer Therapy For Up To $3B Law36008:05 20-Mar-26

Novartis Makes $3bn Bet On Synnovation’s PI3Kα Inhibitor SNV4818 Scrip Pharma Intelligence07:38 20-Mar-26

Novartis strengthens its breast cancer pipeline with $3bn Synnovation acquisition European Pharmaceutical Review07:35 20-Mar-26

Novartis snaps up PI3Kα breast cancer drug in $3bn deal pharmaphorum07:31 20-Mar-26

Novartis to acquire SNV4818 from Synnovation Pharmaceutical Business Review06:42 20-Mar-26

Novartis buys breast cancer treatment from US biotech firm Macau Business06:32 20-Mar-26

Novartis to buy experimental breast cancer drug in up to $3 billion deal The Economic Times06:31 20-Mar-26

BREAKING: Novartis Makes $3bn Bet On Synnovation’s PI3Kα Inhibitor SNV4818 Scrip Pharma Intelligence05:56 20-Mar-26

Novartis to Buy Breast Cancer Drug for as Much as $3 Billion (1) Bloomberg Law05:39 20-Mar-26

STAT Plus: Novartis picks up experimental breast cancer drug for $2B STAT04:33 20-Mar-26

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline Novartis (Press Release)02:16 20-Mar-26

Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Business Wire (Press Release)02:10 20-Mar-26

Novartis leads charge as corps race towards record month in dollars Global Capital18:11 19-Mar-26

Novartis Adds Rare Disease Depth And Cardiovascular Optionality For Investors Simply Wall St14:12 19-Mar-26

Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech Novartis (Press Release)10:41 19-Mar-26

Plans to build more than 200 homes on former Novartis site in Horsham approved SussexWorld10:20 18-Mar-26

Novartis case: Delhi HC pulls up patent office over decade-long delay in breast cancer drug… The Times of India15:36 17-Mar-26

Novartis sells $11 billion bonds to fund avidity acquisition The Hindu Business Line00:49 17-Mar-26

view more headlines

16 Apr 17:14

About our Novartis news

Latest news for Novartis, a global healthcare company based in Switzerland specialising in pharmaceuticals, including updates on company and product news.

Publication filters

Sorry, no headlines or news topics were found. Please try different keywords.